Overview

Incidence of Vivax Along the Thai Burma Border

Status:
Completed
Trial end date:
2014-09-02
Target enrollment:
0
Participant gender:
All
Summary
This is a continuous cohort study consisting of 200 participants (one third 6 months old to 5 years, one third 6 to 15 years old, one third ≥ 15 years old) i.e. a new patient will be recruited (from the same age group) for any patient who develops a Pv infection so that the cohort will always have 200 patients for 3 years. Each patient will be actively followed-up every 8 weeks until Plasmodium vivax infection occurs but the duration of follow up and the number of follow up visits for each patient will vary depending on when or if a vivax infection occurs and when the patient is recruited. Therefore, the minimum follow up period for each patient will be 6 months or time to vivax infection and the maximum will be 3 years if a patient does not get vivax infection and is recruited at the beginning of the study.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Oxford
Collaborator:
Mahidol University
Treatments:
Primaquine
Criteria
Inclusion Criteria:

- Asymptomatic adults and children ≥ 6 months

- Documented P.vivax infection in the last 12 months who have not received radical
treatment with primaquine

- Weight≥ 7 kg for children

- Participant (or parent/guardian if <18 years old) is willing and able to give written
informed consent

- Ability (in the investigators opinion) and willingness of patient or parent/guardian
to comply with all study requirements

Exclusion Criteria:

- History of allergy to primaquine

- Medical conditions such as known chronic diseases (TB, HIV, cardio vascular diseases),
allergies, mental illnesses and similar conditions that could make the interpretation
of symptoms or the follow up difficult.

- Other conditions such as drug addiction, known poor compliance with treatment or
follow up.

- Inability to tolerate oral medication

- Pregnancy

- G6PD deficiency

- Blood transfusion in the last 3 months

- Microscopic evidence of Plasmodium vivax, P.falciparum, P. malariae or ovale

- Fever ≥37.5C